SCHEMBL5043145

SCHEMBL5043145

CO[C@H](C(=O)NCc1ccc(C#N)cc1)c1ccc(OCCOc2ccccc2)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
PPARG P37231 2/20 0.41
HIF1A Q16665 1/20 0.41
FAAH O00519 1/20 0.40
SLC1A3 P43003 1/20 0.40
SLC1A2 P43004 1/20 0.40
TSHR P16473 3/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 2/20 0.40
MMP3 P08254 1/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.39
SCN5A Q14524 1/20 0.39
SCN9A Q15858 1/20 0.39
MAPK1 P28482 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5043135 1.00 PKM (0.44) PKMSMN1; SMN2PPARGHIF1AFAAH
SCHEMBL5037528 0.90 FAAH (0.42) SMN1; SMN2FAAHSLC1A2KMT2AALDH1A1
SCHEMBL5037524 0.90 FAAH (0.42) SMN1; SMN2FAAHSLC1A2KMT2AALDH1A1
SCHEMBL5037450 0.88 GSK3B (0.43) PKMHIF1ATSHRKMT2AALDH1A1
SCHEMBL5037449 0.88 GSK3B (0.43) PKMHIF1ATSHRKMT2AALDH1A1
SCHEMBL5042123 0.88 MMP2 (0.42) PKMHIF1AKMT2AMMP3MEN1
SCHEMBL5042127 0.88 MMP2 (0.42) PKMHIF1AKMT2AMMP3MEN1
SCHEMBL5041820 0.86 HIF1A (0.41) PKMSMN1; SMN2HIF1AALDH1A1LMNA
SCHEMBL5041816 0.86 HIF1A (0.41) PKMSMN1; SMN2HIF1AALDH1A1LMNA
SCHEMBL5040855 0.85 PKM (0.47) PKMHIF1ASLC1A3SLC1A2MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 PKM 4225/4885SMN1; SMN2 3242/4885PPARG 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.